Insight

Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC

Estela Rodriguez/doctors.umiamihealth.org

Jan 25, 2025, 03:46

Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC

Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center, shared a post on X about a recent paper by Solange Peters et al. published in Journal of Thoracic Oncology:

“Long-term outcomes of Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC and tumor PD-L1 lower than 1% provides a long-term, durable clinical benefit, with or without chemotherapy, according to Peters S et al. via Journal of Thoracic Oncology.”

“Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis”

Authors: Solange Peters, Luis Paz-Ares, Martin Reck, Diederik Grootendorst, Suresh Ramalingam et al.

More posts featuring Estela Rodriguez.

cancer Diederik Grootendorst Estela Rodriguez ipilimumab Journal of Thoracic Oncology Luis Paz-Ares Martin Reck nivolumab NSCLC OncoDaily Oncology Solange Peters Suresh Ramalingam

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC